Key result
20-HETE causes dose-dependent increases in blood pressure and coronary resistance that are substantially attenuated in TRPV1 knockout mice and by neurokinin 1 receptor antagonism.
Why the study?
Does 20-HETE activate TRPV1 to regulate vascular function and blood pressure?
Does 20-HETE activate TRPV1 to regulate vascular function and blood pressure?
Answers are grounded in this paper and cite their sources.
20-HETE induces vasoconstriction and elevates blood pressure in part through activation of the TRPV1 channel, identifying a potential therapeutic target for cardiovascular diseases with dysregulated organ blood flow.
A rise in intraluminal pressure triggers vasoconstriction in resistance arteries, which is associated with local generation of the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE). Importantly, dysregulation of 20-HETE synthesis and activity has been implicated in several cardiovascular disease states, including ischemic disease, hypertension, and stroke; however, the exact molecular pathways involved in mediating 20-HETE bioactivity are uncertain. We investigated whether 20-HETE activates the transient receptor potential vanilloid 1 (TRPV1) and thereby regulates vascular function and blood pressure. We demonstrate that 20-HETE causes dose-dependent increases in blood pressure, coronary perfusion pressure (isolated Langendorff), and pressure-induced constriction of resistance arteries (perfusion myography) that is substantially attenuated in TRPV1 knockout mice and by treatment with the neurokinin 1 receptor antagonist RP67580. Furthermore, we show that both channel activation (via patch-clamping of dorsal root ganglion neurons) and vessel constriction are enhanced under inflammatory conditions, and our findings indicate a predominant role for protein kinase A-mediated sensitization of TRPV1 in these phenomena. Finally, we identify a prominence of these pathway in males compared with females, an effect we relate to reduced protein kinase A-induced phosphorylation of TRPV1. 20-HETE-induced activation of TRPV1, in part, mediates pressure-induced myogenic constriction and underlies 20-HETE-induced elevations in blood pressure and coronary resistance. Our findings identify a novel vasoconstrictor 20-HETE/TRPV1 pathway that may offer potential for therapeutic targeting in cardiovascular diseases associated with elevated 20-HETE implicated in dysregulated organ blood flow, such as stroke or hypertension.
No takes yet. Share an insight, caveat, or question.
Bubb et al. (2013) studied Vascular function and blood pressure. 20-HETE vs. TRPV1 knockout or RP67580 treatment was evaluated on Blood pressure, coronary perfusion pressure, and pressure-induced constriction of resistance arteries. 20-HETE causes dose-dependent increases in blood pressure and coronary resistance that are substantially attenuated in TRPV1 knockout mice and by neurokinin 1 receptor antagonism.
Synapse has enriched 10 related papers. Consider them for comparative context: